Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Asymmetric response to ranibizumab in mixed choroidal neovascularization in a neovascular age-related macular degeneration diagnosed on OCT angiography - case report

M. Pencak, M. Veith

. 2021 ; 21 (1) : 42. [pub] 20210115

Language English Country Great Britain

Document type Case Reports, Journal Article

BACKGROUND: To present a case report of a patient with a mixed choroidal neovascular membrane (CNV) with an asymmetric response to ranibizumab diagnosed on optical coherence tomography angiography (OCTa). CASE PRESENTATION: A 61-year-old male was referred to our department in September 2017 due to decreased vision in his left eye. Best-corrected visual acuity (BCVA) was 43 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in the left eye. Macular edema was present in the left eye, and a mixed CNV was identified on the OCTa. Therapy with intravitreal ranibizumab was commenced. After 5 ranibizumab injections, the BCVA was 42 ETDRS letters, and considerable intraretinal edema was still present. OCTa showed a resolution of the type 2 lesion of the mixed CNV; however, the type 1 lesion had continued to grow. The patient was then switched to intravitreal aflibercept. After 3 monthly aflibercept injections, the BCVA improved to 53 ETDRS letters, and a reduction of the edema was observed on the optical coherence tomography (OCT). OCTa showed a decrease in both the area and vessel density in the type 1 lesion of the CNV. Therapy with aflibercept was continued; however, while the intraretinal edema continued to improve, atrophy developed in the macula and the BCVA worsened to 43 ETDRS letters. CONCLUSIONS: Ranibizumab nonresponse in a neovascular age-related macular degeneration is not uncommon. However, to our knowledge, this is the first described case of an asymmetric response to ranibizumab in a mixed CNV. While the type 2 lesion of the CNV reacted swiftly to the ranibizumab therapy, the type 1 lesion continued to grow. As with some other cases of ranibizumab resistance, switching to aflibercept proved effective.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019435
003      
CZ-PrNML
005      
20210830101009.0
007      
ta
008      
210728s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12886-021-01810-z $2 doi
035    __
$a (PubMed)33451290
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Pencak, Martin $u Department of Ophthalmology, Third Faculty of Medicine, Charles University, Prague and University Hospital Kralovske Vinohrady, Srobarova 1150/50, Prague, 100 34, Czech Republic. pencak@volny.cz
245    10
$a Asymmetric response to ranibizumab in mixed choroidal neovascularization in a neovascular age-related macular degeneration diagnosed on OCT angiography - case report / $c M. Pencak, M. Veith
520    9_
$a BACKGROUND: To present a case report of a patient with a mixed choroidal neovascular membrane (CNV) with an asymmetric response to ranibizumab diagnosed on optical coherence tomography angiography (OCTa). CASE PRESENTATION: A 61-year-old male was referred to our department in September 2017 due to decreased vision in his left eye. Best-corrected visual acuity (BCVA) was 43 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in the left eye. Macular edema was present in the left eye, and a mixed CNV was identified on the OCTa. Therapy with intravitreal ranibizumab was commenced. After 5 ranibizumab injections, the BCVA was 42 ETDRS letters, and considerable intraretinal edema was still present. OCTa showed a resolution of the type 2 lesion of the mixed CNV; however, the type 1 lesion had continued to grow. The patient was then switched to intravitreal aflibercept. After 3 monthly aflibercept injections, the BCVA improved to 53 ETDRS letters, and a reduction of the edema was observed on the optical coherence tomography (OCT). OCTa showed a decrease in both the area and vessel density in the type 1 lesion of the CNV. Therapy with aflibercept was continued; however, while the intraretinal edema continued to improve, atrophy developed in the macula and the BCVA worsened to 43 ETDRS letters. CONCLUSIONS: Ranibizumab nonresponse in a neovascular age-related macular degeneration is not uncommon. However, to our knowledge, this is the first described case of an asymmetric response to ranibizumab in a mixed CNV. While the type 2 lesion of the CNV reacted swiftly to the ranibizumab therapy, the type 1 lesion continued to grow. As with some other cases of ranibizumab resistance, switching to aflibercept proved effective.
650    _2
$a inhibitory angiogeneze $x terapeutické užití $7 D020533
650    _2
$a angiografie $7 D000792
650    12
$a neovaskularizace choroidey $x diagnóza $x farmakoterapie $7 D020256
650    _2
$a fluoresceinová angiografie $7 D005451
650    _2
$a lidé $7 D006801
650    _2
$a injekce intravitreální $7 D058449
650    12
$a makulární degenerace $x farmakoterapie $7 D008268
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a ranibizumab $x terapeutické užití $7 D000069579
650    _2
$a optická koherentní tomografie $7 D041623
650    _2
$a výsledek terapie $7 D016896
650    _2
$a zraková ostrost $7 D014792
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Veith, Miroslav $u Department of Ophthalmology, Third Faculty of Medicine, Charles University, Prague and University Hospital Kralovske Vinohrady, Srobarova 1150/50, Prague, 100 34, Czech Republic
773    0_
$w MED00008199 $t BMC ophthalmology $x 1471-2415 $g Roč. 21, č. 1 (2021), s. 42
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33451290 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101010 $b ABA008
999    __
$a ok $b bmc $g 1690289 $s 1139881
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 21 $c 1 $d 42 $e 20210115 $i 1471-2415 $m BMC ophthalmology $n BMC Ophthalmol $x MED00008199
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...